Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab
Yukihiro Toi(Sendai Kousei Hospital), Yoshihiro Honda, Tomoiki Aiba(Sendai Kousei Hospital), Katsuya Suzuki, Keisuke Terayama(Sendai Kousei Hospital), Yosuke Kawashima(Sendai Kousei Hospital), Yutaka Domeki(Sendai Kousei Hospital), Shinsuke Yamanda(Sendai Kousei Hospital), Kyoji Tsurumi(Sendai Kousei Hospital), Hirotaka Ono(Tsuyama Chuo Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Sachiko Kawana(Sendai Kousei Hospital), Yuichiro Kimura(Tohoku University), Atsushi Nakamura(Sendai Kousei Hospital), Hisashi Shimizu, Ryohei Saito(Sapporo Medical University), Jun Sugisaka(Sendai Kousei Hospital)
Cited by 296
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695